The new low-dose transdermal contraceptive system (Twirla®): results from preclinical and Phase III trials
Abstract
A new low-dose, once-a-week contraceptive transdermal delivery system (TDS) with 2.3-mg ethinyl estradiol (EE) and 2.6-mg levonorgestrel (LNG; Twirla ® ) has recently been approved by the US FDA for contraception of women with BMI <30 kg/m 2 . The rationale for developing this new patch, the preclinical study results and the results from two innovative Phase III clinical trials demonstrate that this patch has an acceptable Pearl index (4.3%)...
Paper Details
Title
The new low-dose transdermal contraceptive system (Twirla®): results from preclinical and Phase III trials
Published Date
Jul 1, 2021
Journal
Volume
12
Issue
7
Pages
501 - 514
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History